You are here:
NICE
NICE Guidance
Conditions and diseases
Cancer
Ovarian cancer
Bevacizumab in combination with gemcitabine and carboplatin for treating the first recurrence of platinum-sensitive advanced ovarian cancer
Technology appraisal guidance
Reference number:
TA285
Published:
22 May 2013
Guidance
Tools and resources
Information for the public
Evidence
History
Download guidance (PDF)
Overview
1 Guidance
2 The technology
3 The manufacturer's submission
4 Consideration of the evidence
5 Implementation
6 Related NICE guidance
7 Review of guidance
8 Appraisal Committee members and NICE project team
9 Sources of evidence considered by the Committee
Changes after publication
About this guidance
Changes after publication
January 2014:
minor maintenance.
Next page
About this guidance
Previous page
9 Sources of evidence considered by the Committee